News Sentiment

TLSA sentiment intelligence

Tiziana Life Sciences Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.07 Week of 17 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-13.0% over one week, -7.8% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Tiziana Life Sciences (TLSA) Executive Chairman Increases Stake

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -13.0% Price reacting lower
Trend fit Trend inactive -7.8% over four weeks
Fair value -3.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 30
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 9
TradingView 9
TradingKey 2
Proactive 2
simplywall.st 2
Quiver Quantitative 2
GuruFocus 1

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 14
Deals and strategy 7
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-52 of 52
Stock Titan Direct company coverage

Biotech Tiziana to brief investors on clinical updates at Jefferies event

Tiziana Life Sciences (Nasdaq: TLSA) announced it will present at the Jefferies Global Healthcare Conference on June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide corporate and clinical updates, including advancements for their lead candidate, intranasal foralumab

Tone
Positive 63/100
Event
Market update
Published
28 May 2026 11:08
Source
Stock Titan
Stock Titan Direct company coverage

[6-K] Tiziana Life Sciences Ltd Current Report (Foreign Issuer) | TLSA SEC Filing - Form 6-K

Tiziana Life Sciences (NASDAQ: TLSA) announced it will present at the Jefferies Healthcare Conference in New York City on June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide a corporate presentation highlighting recent clinical and corporate developments, particula

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 11:08
Source
Stock Titan
Market source Direct company coverage

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

Tiziana Life Sciences has fully enrolled its Phase 2a placebo-controlled clinical trial (INFORM-MS) evaluating intranasal foralumab for patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data from this novel anti-CD3 monoclonal antibody study is

Tone
Positive 70/100
Event
Market update
Published
22 May 2026 22:39
Source
Market source